Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

NCT03280264 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Parathyroid Carcinoma
Primary Hyperparathyroidism

Interventions

DRUG: KHK7580

Sponsor

Kyowa Kirin Co., Ltd.